Serum ischemia-modified albumin level returns to its premenopausal level with 1-year hormone therapy in healthy menopausal women.

INTRODUCTION: To assess the effect of hormone therapy (HT) on serum ischemia modified albumin (IMA) levels in healthy menopausal women.
MATERIAL AND METHODS: Thirty surgical menopausal women who were admitted to our menopausal polyclinic during a 1-year period and diagnosed with menopause and planned to have HT for menopausal symptoms were enrolled in this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg estradiol hemihydrate).
RESULTS: The mean age of women was 47.60 ± 2.34 years. The mean serum IMA levels were 0.610 ± 0.096 absorbance units (ABSU) at the beginning and 0.484 ± 0.080 ABSU after 3 months of hormone therapy. Following 6 months of hormone therapy, serum IMA level was 0.546 ± 0.075, and reached 0.580 ± 0.089 ABSU following 12 months of therapy.
CONCLUSIONS: These findings suggest that HT may not block the menopause induced ischemia process. Although HT had a positive effect on serum IMA levels following 3 months' use, serum IMA levels returned to baseline levels after 12 months' use. Based on this study's findings, long-term use of HT may not have a positive effect on cardiovascular disease protection. Copyright:

Introduction

The protective effect of ovarian activity on diseases of the cardiovascular system in women is known. Accordingly, there is an increased risk of cardiovascular disease (CVD) in menopause. In studies conducted to date, estrogen had positive effects on the cardiovascular system and had a cardioprotective effect. Data in recent years have questioned the notion, which has been believed for many years, that hormone therapy (HT) has a protective effect on the development and progression of coronary artery disease (CAD). Until the release of the Women’s Health Initiative (WHI) study, HT was given for menopausal symptoms and treatment was extended until later menopausal periods, believing that it reduced the risk of CVD. This belief arises from the fact that almost all observational studies indicate that HT reduces the risk of CVD and that there has been a lot of evidence available that these treatments have a positive effect on the lipid pattern and maintain vascular functions. As a result of the WHI study, it was suggested that HT should not be started for the primary prevention of CAD and treatment should not be continued in patients who received it before [1].

Hormone therapy in the case of menopause does not provide benefit in terms of eliminating the risks of cardiovascular diseases. However, it provides important benefits in terms of preventing vasomotor symptoms, genitourinary atrophy symptoms and osteoporosis due to menopause. Hormone therapy is also useful in preventing chronic systemic diseases that increase morbidity during menopause [2].

Acute ischemic events increase suddenly in women after menopause. Estrogen deficiency is the main factor responsible for this change. Estrogen reduces cell hypertrophy, increases the elasticity of the vascular wall, and causes less luminal narrowing, although it is likely to be at the same rate as atherosclerosis. With the menopause process, an increase in cholesterol levels is observed. In this process, there is also a tendency to coagulation due to an increase in procoagulant factor VII, fibrinogen and plasminogen activator inhibitor-1 levels in the hemostatic system in the menopause. This explains the increased ischemic conditions after menopause [3, 4].

In our previous study [5], it was found that HT in menopausal patients with obesity as a cardiovascular risk factor decreased serum ischemia-modified albumin levels at 3 and 6 months of use. However, in the literature it has not been clear whether this effect occurs in healthy menopause cases and whether this effect continues after one year of use.

This study aimed to investigate the level of ischemia-modified albumin (IMA) in healthy patients with surgical menopause and thus evaluate the reversible effect of HT on the ischemic process.

Material and methods

Thirty consecutive women, 45–55 years old, who were evaluated for surgical menopause (having a history of total abdominal hysterectomy and bilateral salpingoophorectomy (TAH + BSO) for benign reasons) at the current clinic, and suitable for HT use, were evaluated for this prospective study. Ethic committee approval was obtained from the Research Ethics Committee dated 29.06.2009 and numbered 2009/54.

Case selection

During the 10-month study period, 190 surgical menopausal women who had undergone TAH + BSO operation in our clinic were evaluated in terms of inclusion criteria. Estradiol hemihydrate (Estrofem film tablet, Novo Nordisk, Istanbul, Turkey) was prescribed to the patients who met the inclusion criteria in the sixth week after TAH + BSO.

Criteria for inclusion in the research:

accepting consent to participate in the trial and signing the form,

surgical menopausal women aged 45–55 (having TAH + BSO for benign reasons),

presence of vasomotor or menopausal symptoms (moderate to severe),

no systemic disease or infectious disease in the past 2 weeks,

not taking any other HT or medication until 6th postoperative week,

no contraindications for HT in routine menopause evaluation,

willingness to take HT,

no smoking.

Criteria for exclusion from the study:

any systemic disease presence (such as diabetes, hypertension, coronary artery disease, hyperlipidemia, endocrine, renal or pulmonary diseases (n = 76),

smoking (n = 33, in addition, 16 women had a history of both systemic disease and smoking),

contraindications for HT (n = 11),

failure to follow-up (n = 18),

inability to complete the three months of HT (n = 14),

quitting HT or other medical reasons during HT (n = 4),

cases reported as preinvasive and invasive genital tumors as a result of TAH + BSO (n = 3),

cases reported as suspicious findings in the mammography report (n = 2).

A blood sample was taken four times during the study, just before starting HT (at 6 weeks after TAH + BSO), at 3 months of HT, at 6 months of HT, and at 12 months of HT. After 8 hours of fasting in each period, 5–7 cc of blood sample was drawn into a heparin-free biochemistry tube around 8.00–9.00 a.m. All blood samples were centrifuged at 900 g for 10 minutes and collected in the cabinets of the Biochemistry Department at –80°C until all the blood samples collection were completed.

Hormone therapy usage posology

Estradiol hemihydrate containing preparations (Estrofem film-coated tablets, 2.0 mg, Novo Nordisk, Istanbul, Turkey, 12 boxes) were given and 1 tablet per day (2 mg/day) was prescribed. Patients were recommended to reapply at the 3rd, 6th, and 12th months of treatment following drug usage.

Measuring serum ischemia-modified albumin level

After collecting all blood samples, serums were re-dissolved, and serum IMA levels were checked. IMA level was evaluated by the rapid colorimetric method developed by Barr-Or as an absorbance unit [6]. For IMA, the results were recorded in the spectrophotometer at appropriate wavelengths, and the results were recorded as absorbance units (ABSU).

Statistical methods

All data were entered by coding in the SPSS 10.0 package program. One way analysis of variance (with Bonferroni correction) was performed in the related sample. P-values < 0.05 were considered statistically significant.

Results

The mean age in the study group was 47.60 ± 2.34 years. The general clinical features of the patients are given in Table 1. The most common TAH + BSO indication was determined as myoma uteri (46.7%).

Table 1

General clinical features in the research group

Clinical features
Age (years)	47.60 ± 2.34 (45–52)
Weight (kg)	74.43 ± 10.83 (51–93)
BMI (kg/m<sup>2</sup>)	26.31 ± 2.25 (22–30)
Gravida (no.)	5.03 ± 2.55 (0–10)
Parity (no.)	3.87 ± 1.85 (0–8)
Indication of TAH + BSO (%)a
Myoma uteri, abnormal uterine bleeding	14 (46.7%)
Dysfunctional uterine bleeding	10 (33.3%)
Abnormal uterine bleeding, endometrial hyperplasia	5 (16.7%)
Ovarian cyst	1 (3.3%)
TAH + BSO Pathology Results (%)a
Myoma uteri	14 (46.7%)
Simple type atypical endometrial hyperplasia	5 (16.7%)
Simple type atypia-free endometrial hyperplasia + myoma uteri	7 (22.1%)
Complex type atypia-free endometrial hyperplasia	3 (9.9%)
Serous cystadenoma	1 (3.3%)

Mean ± standard deviation and minimum, maximum values in parentheses are given.

BMI – body mass index, TAH + BSO – total abdominal hysterectomy and bilateral salpingoophorectomy,

– number of cases and percentages in parentheses are given

While the mean serum IMA level before HT was 0.610 ± 0.096 ABSU, the mean serum IMA level was 0.484 ± 0.080 ABSU in the 3rd month, 0.546 ± 0.075 ABSU in the 6th month, and 0.580 ± 0.089 ABSU in the 12th month after hormone therapy. The change and statistical analysis (one way analysis of variance in related sample, Bonferroni correction) of serum mean IMA levels before and after HT (3rd, 6th, and 12th months) in the study group are given in Table 2.

Table 2

Changes and statistical analysis of serum mean ischemia modified albumin levels before and after hormone therapy (3rd, 6th, and 12th months) in the study group

Groups		Mean change	p	95% CI
Before HT	3rd month after HT	0.126 ± 0.022	< 0.001	0.067–0.185
	6th month after HT	0.064 ± 0.022	0.025	0.005–0.123
	12th month after HT	0.031 ± 0.022	0.999	–0.028–0.089
3rd month after HT	6th month after HT	–0.061 ± 0.022	0.035	–0.121 to –0.002
6th month after HT	12th month after HT	–0.033 ± 0.022	0.775	–0.0225–0.092

Mean values ± standard deviation values are given. One way analysis of variance in the associated sample, with Bonferroni correction test was used.

IMA – ischemia modified albumin, HT – hormone therapy

In the study group, in the 3rd month after hormone therapy, there was a statistically significant decrease in the serum IMA level of 0.126 ± 0.022 ABSU according to the pre-condition (one way analysis of variance in the associated sample, with Bonferroni correction p < 0.001). However, this decrease in serum IMA level disappeared after using HT for 12 months and increased to be close to the state before hormone therapy.

The change in serum mean ischemia-modified albumin (IMA) levels before and after HT in the study group is given in Figure 1.

Fig. 1

Change of serum mean ischemia modified albumin levels before and after hormone therapy in the study group (3rd, 6th, and 12th months)

No side effects were detected in any patient during 12 months of HT.

Discussion

Cardiovascular diseases constitute the main cause of mortality in women and men. The risk of cardiovascular disease, which is low in women before the menopause, increases rapidly with aging, especially in the period after menopause [7]. The increase in the protective effect of endogenous estrogen with the development of menopause is held responsible for this risk [8].

Hormone therapy is effective in the coagulation and fibrinolytic system. For many years, this effect has been thought to reduce the risk of myocardial infarction and deep vein thrombosis. However, recent studies have shown that, while reducing the risk of myocardial infarction in the future, it increases the risk of venous thromboembolism. It has been determined that young women with early ovarian failure have a lower vascular endothelial function than women with regular menstrual periods of similar age, and have a higher risk of CVD. It succeeded in reversing HT endothelial dysfunction for 6 months in young women with early ovarian failure [9]. However, there have also been studies showing that HT was ineffective or partially effective in correcting endothelial functions [9, 10]. The endothelium of elderly patients with multiple risk factors was more unresponsive to HT. Endothelial dysfunction with menopause improved with HT in healthy postmenopausal women; however, this effect was not observed in elderly women with multiple cardiovascular risk factors [11]. The negative effect of HT on endothelial functions was directly related to the time since menopause. Estrogen affected endothelial functions more positively in the first 5 years after menopause compared to use more than 5 years later [12].

In the light of observational studies up to the last 10 years, postmenopausal HT was thought to protect the woman from cardiovascular events. Indeed, in many experimental and animal studies, estrogen has been a cardioprotective agent [13-15], and observational studies in women using HT found that the risk of CAD was reduced by 35–50% [16, 17]. However, recent randomized studies have not confirmed the observational study data and raised doubts about HT use by showing that HT does not have clinical benefits in either primary or secondary protection cardiac aspects [18, 19].

In a meta-analysis of observational studies conducted until 2000, the beneficial effects of HT on cardiovascular mortality and CAD frequency draw attention [20]. Based on these results, health authorities including the American College of Physicians recommended HT to protect against CAD in postmenopausal women in 1992 [21], and a significant increase in HT use was observed after that date [22]. However, these studies were based on observational data, and when sub-analyses were matched in terms of socioeconomic level and major CAD risk factors, HT lost its protective feature.

When recent prospective studies were examined, a possible relationship was found between postmenopausal obesity and circulating high IMA levels due to oxidative stress [4]. In that study, IMA was measured in the early period. It did not match our current study. The reason for that was the evaluation of long-term results such as 1 year by looking at IMA 4 times as in our study. In another study in 2013 where obese menopausal patients were evaluated, after hormone therapy, IMA levels, CD40 ligand, and platelet levels were evaluated at 3-month and 6-month follow-ups. When the HT study group and control group were compared, it was found that CD40 ligand levels did not decrease, and IMA levels decreased at the end of 6 months. They also stated that platelet levels increased. As a result, they reported that menopause was associated with an increased risk of obesity and associated cardiovascular risk increase, changes in metabolic and endocrine status, and transition to oxidative stress and transition to abdominal fat distribution [5]. In our current study, although early results were consistent in terms of IMA levels, long-term results did not match. The fact that the evaluated cases were patients with obese menopause in the published paper was the main difference from our current study. Another important distinction was that our presented research had long-term IMA data in normal weight surgical menopausal cases.

HERS is the first large-scale randomized clinical trial to examine the relationship between HT and CVD [17]. There was no difference between the groups in terms of non-fatal MI or cardiac death at the end of the four-year follow-up period. An interesting result of the study was the increase in cardiovascular disease-related risk in the group receiving HT in the first year following randomization and a decrease in the following years.

The WHI study initiated in 1991 is the most comprehensive prospective randomized study to date, aimed at determining the role of HT in primary cardiovascular protection in healthy postmenopausal women. Similar to the results of the HERS study, it was noteworthy that increases in CAD risk were observed especially in the first year [1].

In the current study, estrogen therapy was started in patients between the ages of 45 and 55, who did not carry any risk factors for CVD in the postmenopausal period after hysterectomy, and was followed for a year. IMA, an ischemia marker, was used for the risk screening of CVD, and although at the end of the 3rd month IMA levels were low, an increase in IMA levels was observed at the end of 1 year. Results were similar to the values determined at the beginning of HT. These findings are consistent with the WHI and HERS studies; we found that HT does not prevent the ischemic process due to menopause.

According to the results of the study on serum IMA in menopause cases, mean serum IMA level in obese menopause cases was 115 while it was 97 in non-obese menopause cases. Likewise, in menopausal cases with CAD the mean serum IMA level was 117; it was higher than menopausal subjects who were obese or not. This suggests that serum IMA may also be an important marker in menopause cases in terms of showing coronary disease [4].

Starting HT in young, healthy, menopausal patients may restore endothelial dysfunction and may slow down the early stages of development of atherosclerosis. In postmenopausal women aged 45–55 years, we think that HT would be of benefit in the early stages of menopause. However, it should not be recommended to start HT in postmenopausal women for protection against CVD until the results of some ongoing randomized studies are published. It should not be forgotten that there may be many more proven protection methods (such as a healthy diet, regular physical exercise, blood pressure control, diabetes, and dyslipidemia treatment) in this regard.

The strength of the research was that it gave the long-term results of the ischemic process in menopause. The low number of cases seemed to be the most important limitation of the study. Another limiting aspect of the research was that only the one-year HT effect was investigated. Planning research including five-year results may reveal the accuracy of our results.

Conclusions

In this study, increasing IMA levels after one year of HT did not support the argument that HT given during menopause might prevent the ischemic process. The ischemic condition has been in question in menopause. This ischemic process returned in the short term with HT, but long-term treatment did not effectively correct ischemia. This supported the view that HT did not prevent ischemic status, as stated in the WHI study. Our study yielded results for only one year. Further research is needed to generate 5-year results. Nevertheless, according to the results of this study, the message to take home should be as follows: In postmenopausal cases, HT did not provide any benefit in terms of preventing the ischemic state that caused cardiovascular disease.

Disclosure

The authors report no conflict of interest.